News >

FDA Delays Decision on Lenvatinib for HCC

Silas Inman @silasinman
Published: Friday, May 25, 2018

Masatoshi Kudo, MD

Masatoshi Kudo, MD
The FDA has extended the review period for lenvatinib (Lenvima) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), to allow ample time to review the application, according to Eisai and Merck, the companies codeveloping the drug. The new action date for the supplemental new drug application (sNDA) is August 24, 2018.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication